Bloomberg Finance Expert Converts Article into Concise Title.

The article discusses the company's quarterly financial results, highlighting revenue growth of 15% year-over-year to $9.3 billion and a 7% increase in net income to $1.3 billion. The company's adjusted EBITDA also rose 12% to $2.8 billion, driven by strong performance in its cloud, security, and customer experience segments. The CEO notes that the company is well-positioned for future growth, with a strong product portfolio and increasing demand for its services.

NeurAxis, Inc. (NRXS) reported robust financial performance for the fourth quarter of 2024, with shares gaining 0.9% since the earnings release. This positive performance compares favorably to the S&P 500 Index, which declined 0.1% over the same period. Over the past month, NeurAxis stock has climbed 3.2%, while the S&P 500 saw a 5% decline [1].

The company reported fourth-quarter 2024 revenues of $761,000, a 43% increase from $531,000 a year earlier. This growth was primarily driven by a 45% increase in unit sales, reflecting stronger adoption of the company's IB-Stim therapy through both insurance-covered treatments and the company’s financial assistance program. For the full year, revenues rose 9.2% to $2.7 million from $2.5 million in 2023 [1].

Gross margin remained stable at 86.4% in the fourth quarter, unchanged from a year ago. Operating loss in the fourth quarter of 2024 was $1.5 million compared with $1.6 million in the fourth quarter of 2023. Net loss for the quarter was $1.5 million compared with $5.3 million in the prior-year period, aided by the absence of a $3.7 million debt extinguishment charge incurred during the company’s 2023 IPO. Cash at year-end was $3.7 million, with no long-term debt and only $154,000 in short-term obligations [1].

The company has treated more than 1,000 pediatric patients in the past year, a small fraction of the estimated 600,000 children in the United States affected by debilitating IBS symptoms. Management noted that this highlights the scale of the addressable market and underscores the opportunity for accelerated revenue growth as policy coverage improves [1].

The CEO, Brian Carrico, characterized the fourth quarter as the culmination of a transformational year, noting NRXS’ progress in expanding insurance coverage from 4 million to 51 million covered lives. He highlighted three key milestones, including the CPT Category I code approval (effective Jan. 1, 2026), expansion of the IB-Stim label to cover ages 8–21 (up from 11–18), and FDA clearance for the company’s new Rectal Expulsion Device (RED) [1].

The development of a second-generation IB-Stim device is underway, with enhancements including user feedback indicators and potential integration of diagnostic capabilities. The company targets a 2026 release [1].

References:
[1] https://www.tradingview.com/news/zacks:2a9b82ddb094b:0-neuraxis-stock-gains-post-q4-earnings-and-revenue-growth/